Silodosin is a pharmaceutical compound primarily used for the treatment of benign prostatic hyperplasia (BPH), a condition characterized by an enlarged prostate. It belongs to the class of alpha-1 adrenergic receptor antagonists, specifically targeting the alpha-1A subtype, which is predominantly found in the prostate and bladder neck. This selective action helps to relax smooth muscle in these areas, thereby improving urinary flow and reducing symptoms associated with BPH. Silodosin is typically administered orally and is known for its favorable pharmacokinetic profile, including a relatively short half-life and high bioavailability. The compound is characterized by its chemical structure, which includes a piperidine ring and a phenyl moiety, contributing to its pharmacological activity. Common side effects may include dizziness, retrograde ejaculation, and nasal congestion. As with any medication, it is essential for patients to consult healthcare professionals for appropriate usage and potential interactions with other drugs.

Silodosin

160970-64-9: (-)-1-(3-Hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-di-hydro-1H-indole-7-carboxamide, 1-(3-Hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-dihydro-1H-indole-7-carboxamide, 1H-Indole-7-carboxamide, 2,3-dihydro-1-(3-hydroxypropyl)-5-[2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-, 1H-Indole-7-carboxamide,2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-, 2,3-Dihydro-1-(3-hydroxypropyl)-5-[2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carboxamide, Kad 3213, Kmd 3213, Silodoxin

CAS 160970-64-9: Silodosin

rac-Silodosin

Ref: 4Z-S-2511

rac-Silodosin

Ref: ST-EA-CP-S8007